<div class="docx-content">
<p><strong>FRCPath Part 2 Revision Notes – <em>Mycobacterium</em></strong> <em>(Integrated from UK‑SMI B 40 i7.3, ATS/ERS/ESCMID/IDSA 2020, BTS 2017, WHO TB Consolidated Guidelines 2024/25, NICE NG33 2024, CLSI M24‑A4 2024, UKHSA WGS &amp; TB Action Plan)</em></p><h2 class="text-xl font-semibold mt-6 mb-3"><strong>1  Taxonomy &amp; Key Pathogens</strong></h2><table><tr><td><p><strong>Runyon</strong></p></td><td><p><strong>Growth rate / Pigment</strong></p></td><td><p><strong>Representative species</strong></p></td><td><p><strong>Typical disease</strong></p></td><td><p><strong>Exam pearls</strong></p></td></tr><tr><td><p><strong>I Photochromogens</strong></p></td><td><p>Slow, yellow‑orange after light</p></td><td><p><em>M. kansasii</em>, </p><p><em>M. marinum</em></p></td><td><p>Pulmonary cavitary (kansasii); fish‑tank granuloma (marinum)</p></td><td><p><em>M. kansasii</em> rif‑susceptible, niacin‑neg</p></td></tr><tr><td><p><strong>II Scotochromogens</strong></p></td><td><p>Slow, pigment in dark</p></td><td><p><em>M. gordonae</em></p><p><em>M. scrofulaceum</em>, </p></td><td><p>Contaminant (gordonae)</p><p>Cervical nodes (scrofulaceum); </p></td><td><p>Gordonae = “tap‑water” bacillus</p></td></tr><tr><td><p><strong>III Non‑photochromogens</strong></p></td><td><p>Slow, non‑pigmented</p></td><td><p><em>M. avium</em> complex, </p><p><em>M. xenopi</em>, </p><p><em>M. haemophilum</em></p></td><td><p>Chronic lung, disseminated AIDS (MAC);</p><p>nodular bronchiectasis (xenopi); </p><p>skin (<em>haemophilum)</em></p></td><td><p><em>M. haemophilum</em> grows at 30 °C with Fe³⁺</p></td></tr><tr><td><p><strong>IV Rapid growers</strong></p></td><td><p>Colonies ≤7 d</p></td><td><p><em>M. abscessus</em> complex, </p><p><em>M. fortuitum</em>, </p><p><em>M. chelonae</em></p></td><td><p>SSTI, CF bronchiectasis, device infections</p></td><td><p>Check <strong>erm(41)</strong> for inducible macrolide R</p></td></tr><tr><td><p><strong>MTB complex</strong></p></td><td><p>Slow, non‑pigmented</p></td><td><p><em>M. tuberculosis</em>, </p><p><em>M. bovis</em>, </p><p><em>M. africanum</em>, </p><p><em>M. canettii</em>, </p><p><em>M. caprae</em></p></td><td><p>Pulmonary &amp; extra‑pulmonary TB</p></td><td><p>Niacin +/-, NAP inhibited</p></td></tr></table><h2 class="text-xl font-semibold mt-6 mb-3"><strong>2  Biosafety &amp; Infection‑control</strong></h2><ul><li>Hazard Group 3 (ACDP) for MTBC and most NTMs – work in CL3 if aerosol‑generating (smear prep, MGIT positives).</li><li>Class II MSC, sealed buckets ≥3000 g 15 min, negative‑pressure rooms for induced sputum.</li><li>Decontaminate work surfaces with 1 % hypochlorite (10 000 ppm) or 70 % ethanol followed by UV.</li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>3  Specimen Collection &amp; Transport</strong></h2><table><tr><td><p>Specimen</p></td><td><p>Points</p></td></tr><tr><td><p><strong>Sputum</strong></p></td><td><p>≥2 (ideally 3) early‑morning, 5 mL, tight‑lidded pot.</p></td></tr><tr><td><p><strong>BAL / washings</strong></p></td><td><p>For smear‑neg or non‑productive; avoid tap‑water contamination.</p></td></tr><tr><td><p><strong>Gastric aspirate (children)</strong></p></td><td><p>Neutralise with Na₂CO₃ if delay &gt; 4 h.</p></td></tr><tr><td><p><strong>Sterile fluids / tissue</strong></p></td><td><p>No decontamination; send fresh (no formalin).</p></td></tr><tr><td><p><strong>Urine</strong></p></td><td><p>Three consecutive early‑morning, no boric acid.</p></td></tr><tr><td><p><strong>Blood / bone‑marrow</strong></p></td><td><p>Culture in Myco/F Lytic bottle.</p></td></tr><tr><td><p>Transport within 24 h, refrigerate 4 °C if delayed.</p></td><td></td></tr></table><h2 class="text-xl font-semibold mt-6 mb-3"><strong>4  Laboratory Diagnosis Workflow</strong></h2><h3 class="text-lg font-semibold mt-6 mb-3"><strong>4.1  Front‑end Molecular Tests</strong></h3><ul><li><strong>Xpert MTB/RIF Ultra</strong>: LoD ~16 CFU/mL; detects <em>rpoB</em> Rif R.</li><li><strong>Xpert MTB/XDR (2023 UK roll‑out)</strong>: adds isoniazid (<em>katG</em>, <em>inhA)</em>, quinolone (<em>gyrA/B)</em>, aminoglycoside (<em>rrs/eis)</em>; 90 min.</li><li>Positive rifampicin‑resistant or smear‑positive specimens proceed to <strong>WGS</strong> for full resistance prediction and cluster typing (UKHSA).</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>4.2  Homogenisation / Decontamination</strong></h3><ul><li>Preferred: <strong>NALC–NaOH</strong> (final 1 % NaOH, 0.5 % NALC) 15 min → neutralise pH 6.8 phosphate buffer, centrifuge 3000 g 15 min.</li><li>Alternative: 5 % oxalic acid for heavily P. aeruginosa‑contaminated CF sputum.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>4.3  Microscopy</strong></h3><ul><li>Auramine‑phenol primary (LED fluorescence) → Ziehl‑Neelsen less sensitive but gives morphological detail.</li><li>Report grading (WHO/IUATLD): 0, scanty (1–9 AFB/100 fields), 1+, 2+, 3+.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>4.4  Culture</strong></h3><ul><li><strong>Liquid</strong>: MGIT 960 (⁓10 d positivity), VersaTREK.</li><li><strong>Solid</strong>: Löwenstein–Jensen / Middlebrook 7H10 &amp; 7H11; incubate 37 °C (and 30 °C if <em>M. haemophilum</em> suspected), retain 8 wks.</li><li>Contamination action limit ≤5 % (MGIT); monitor monthly.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>4.5  Identification</strong></h3><ul><li>MALDI‑TOF (Bruker database v11+),</li><li>line‑probe assays (GenoType Hain), </li><li>16S/hsp65/rpoB sequencing.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>4.6  Drug‑Susceptibility Testing (DST)</strong></h3><table><tr><td><p>Method</p></td><td><p>Organisms</p></td><td><p>Notes</p></td></tr><tr><td><p><strong>MGIT 960 SIRE/PZA</strong></p></td><td><p>MTBC</p></td><td><p>Critical conc per CLSI M24‑A4; QC <em>H37Rv</em> ATCC 27294.</p></td></tr><tr><td><p><strong>Broth microdilution (Sensititre RAPMYCO)</strong></p></td><td><p>NTM</p></td><td><p>Test macrolide &amp; amikacin for MAC/abscessus; report MICs.</p></td></tr><tr><td><p><strong>Rapid molecular</strong></p></td><td><p>GeneXpert, LPAs, tNGS/WGS</p></td><td><p>Interpret mutations (e.g. <em>katG S315T</em> high‑level INH R).</p></td></tr></table><p>Quality control: weekly QC strains (<em>M. avium</em> ATCC 700898, <em>M. kansasii</em> ATCC 12478), MGIT positive &amp; negative controls each run; document under ISO 15189.</p><h2 class="text-xl font-semibold mt-6 mb-3"><strong>5  Public Health &amp; Genomics</strong></h2><ul><li><strong>Statutory notification</strong> of TB within 24 h (online ETS).</li><li><strong>WGS</strong>: SNP cut‑off ≤5 SNPs suggests recent transmission; triggers incident meeting.</li><li><strong>Contact tracing</strong>: concentric circles, risk matrix (smear ++, cavitary, household, paediatric). Follow 2021–26 UKHSA TB Action Plan.</li><li><strong>EQA</strong>: UK NEQAS AFB smear, culture, identification &amp; DST schemes.</li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>6  Treatment &amp; Management</strong></h2><h3 class="text-lg font-semibold mt-6 mb-3"><strong>6.1  Drug‑susceptible TB (adults)</strong></h3><table><tr><td><p>Phase</p></td><td><p>Regimen</p></td><td><p>Duration</p></td></tr><tr><td><p>Intensive</p></td><td><p>R + H + Z + E</p></td><td><p>2 months</p></td></tr><tr><td><p>Continuation</p></td><td><p>R + H</p></td><td><p>4 months</p></td></tr></table><h3 class="text-lg font-semibold mt-6 mb-3"><strong>6.2  DR‑TB (WHO Module 4, Apr 2025)</strong></h3><ul><li><strong>Short all‑oral regimen (BPaLM)</strong>: bedaquiline 400 mg qd 2 wks then 200 mg thrice‑weekly + pretomanid 200 mg qd + linezolid 600 mg qd + moxifloxacin 400 mg qd for 6–9 mo.</li><li>Monitor ECG (QTc &gt;500 ms), LFTs, weekly FBC for linezolid.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>6.3  Non‑tuberculous Mycobacteria</strong></h3><table><tr><td><p>Scenario</p></td><td><p>Preferred regimen</p></td><td><p>Comments</p></td></tr><tr><td><p><strong>MAC – nodular/bronchiectatic</strong></p></td><td><p>3× weekly azithro 500 mg + rifampicin 600 mg + ethambutol 25 mg/kg</p></td><td><p>≥12 mo post‑conversion</p></td></tr><tr><td><p><strong>MAC – cavitary / severe</strong></p></td><td><p>Daily azithro 250–500 mg </p><p>+ rifampicin </p><p>+ ethambutol </p><p><strong>± IV amikacin</strong> first 2–3 mo</p></td><td><p>Add ALIS if culture‑pos ≥6 mo</p></td></tr><tr><td><p><strong>M. kansasii</strong></p></td><td><p>Daily rifampicin </p><p>+ ethambutol </p><p>+ INH <em>or</em> azithro</p></td><td><p>12 mo total</p></td></tr><tr><td><p><strong>M. xenopi</strong></p></td><td><p>Rifampicin </p><p>+ ethambutol </p><p>+ moxifloxacin/macrolide </p><p><strong>± IV amikacin</strong></p></td><td><p>High relapse</p></td></tr><tr><td><p><strong>M. abscessus (erm neg)</strong></p></td><td><p><strong>Intensive ≥2 mo</strong>: </p><p>IV amikacin </p><p>+ imipenem/cefoxitin </p><p>+ azithro </p><p><strong>Continuation</strong>: </p><p>azithro </p><p>+ clofazimine </p><p>± inhaled amikacin</p></td><td><p>≥12 mo neg</p></td></tr><tr><td><p><strong>M. abscessus</strong></p><p><strong> (erm pos / mac‑R)</strong></p></td><td><p>Same IV backbone, macrolide for immunomodulation only; consider tigecycline, bedaquiline, linezolid; surgical resection</p></td><td><p>Specialist input</p></td></tr></table><p>Refer also to <strong>BTS Pulmonary NTM PD Guideline 2017</strong> for UK surgical thresholds &amp; airway clearance</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>6.4  Monitoring &amp; Toxicity</strong></h3><table><tr><td><p>Drug</p></td><td><p>Monitoring</p></td><td><p>Major toxicities</p></td></tr><tr><td><p>Rifampicin</p></td><td><p>Baseline/ monthly LFT, </p><p>drug‐interactions</p></td><td><p>Hepatitis, thrombocytopenia</p></td></tr><tr><td><p>Isoniazid</p></td><td><p>LFT, </p><p>neuropathy prophylaxis with pyridoxine</p></td><td><p>Hepatitis, neurotoxicity</p></td></tr><tr><td><p>Ethambutol</p></td><td><p>Visual acuity/colour monthly</p></td><td><p>Optic neuritis</p></td></tr><tr><td><p>Pyrazinamide</p></td><td><p>LFT, uric acid</p></td><td><p>Hepatotoxicity, arthralgia</p></td></tr><tr><td><p>Bedaquiline</p></td><td><p>ECG baseline &amp; monthly</p></td><td><p>QT prolongation</p></td></tr><tr><td><p>Linezolid</p></td><td><p>Weekly FBC, </p><p>visual symptoms</p></td><td><p>Cytopenias, neuropathy</p></td></tr><tr><td><p>Amikacin</p></td><td><p>Creatinine monitoring, </p><p>audiogram</p></td><td><p>Nephro‑/ototoxicity</p></td></tr></table><h2 class="text-xl font-semibold mt-6 mb-3"><strong>7  Surgery &amp; Adjuncts</strong></h2><ul><li>Consider lobectomy/pneumonectomy for localised cavitary or mac‑R disease with good reserve.</li><li>Corticosteroids only for paradoxical IRIS.</li><li>ALIS (amikacin liposome inhalation) licensed for refractory MAC.</li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>8  Quality &amp; Accreditation (ISO 15189 hot points)</strong></h2><ul><li>IQC logs: smear pos/neg, MGIT growth control, lot acceptance.</li><li>Contamination index ≤5 % (liquid); action if &gt; 10 %.</li><li>Staff competency, risk assessments, annual CL3 airflow validation.</li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>9  High‑Yield Exam Pearls</strong></h2><ol><li><strong>NALC–NaOH ≤15 min</strong> – most mycobacteria survive.</li><li><em>M. kansasii</em> = photochromogen, nitrate +, rif‑S.</li><li>Inducible <strong>erm(41)</strong> causes macrolide R in <em>M. abscessus</em> after 14 d incubation.</li><li><strong>Xpert Ultra ‘trace’</strong> → treat as TB if high pre‑test probability.</li><li><strong>BPaLM</strong> now first‑line for MDR/RR‑TB in adults ≥14 y.</li><li>MGIT PZA false‑R if pH &gt;6 or inoculum &gt;0.5 McF.</li><li>Visual monitor ethambutol if &gt;15 mg/kg or paediatric.</li><li>WGS SNP distance ≤5 suggests recent transmission in UKHSA algorithm.</li></ol><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Key Documents to Read</strong></h3><ul><li>UK‑SMI B 40 i7.3 (Oct 2020)</li><li>WHO TB Consolidated Guidelines – Module 3 (Mar 2024) &amp; Module 4 (Apr 2025)</li><li>NICE NG33 Tuberculosis (Feb 2024 update)</li><li>ATS/ERS/ESCMID/IDSA NTM Guideline 2020 (ciaa241)</li><li>BTS Guideline 2017 – NTM Pulmonary Disease</li><li>CLSI M24‑A4 2024 – Susceptibility Testing of <em>Mycobacteria</em></li><li>UKHSA TB WGS &amp; Cluster Investigation Handbook 2022</li></ul>
</div>